Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.


Journal

Physiological research
ISSN: 1802-9973
Titre abrégé: Physiol Res
Pays: Czech Republic
ID NLM: 9112413

Informations de publication

Date de publication:
17 03 2021
Historique:
pubmed: 18 1 2021
medline: 15 12 2021
entrez: 17 1 2021
Statut: ppublish

Résumé

Glomerular hyperfiltration is observed in an early stage of kidney diseases including diabetic nephropathy. A better understanding of pathophysiological changes in glomerular hyperfiltration is essential for development of new therapies to prevent kidney disease progression. In this study, we investigated glomerular changes including glomerular filtration rate (GFR) and glomerular size in the Spontaneously Diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model, and we also evaluated pharmacological effects of the sodium glucose cotransporter 2 inhibitor dapagliflozin on the renal lesions. Dapagliflozin was administered to SDT fatty rats from 5 to 17 weeks of age. Blood and urinary biochemical parameters were periodically measured. GFR was determined by transdermal GFR monitor at 16 weeks of age and histopathological analysis was performed at 17 weeks of age. SDT fatty rat developed severe hyperglycemia and exhibited pathophysiological abnormalities in the kidney, such as an increased GFR, glomerular hypertrophy and tissue lesions. Dapagliflozin achieved good glycemic control during the experimental period, inhibited the increase in GFR, and improved histopathological abnormalities in tubules. These results suggest that the SDT fatty rat is a useful model for analyzing the pathogenesis of diabetic nephropathy during its early stage and dapagliflozin improves not only hyperglycemia but also glomerular hyperfiltration and tubule lesions in SDT fatty rat.

Identifiants

pubmed: 33453716
pii: 934533
doi: 10.33549/physiolres.934533
pmc: PMC8820518

Substances chimiques

Benzhydryl Compounds 0
Glucosides 0
Sodium-Glucose Transporter 2 Inhibitors 0
dapagliflozin 1ULL0QJ8UC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-54

Références

Exp Anim. 2015;64(2):161-9
pubmed: 25736710
Clin Exp Pharmacol Physiol. 2020 Apr;47(4):583-590
pubmed: 31868944
PLoS One. 2016 Jan 07;11(1):e0144640
pubmed: 26741142
Diabetes Care. 2014 Oct;37(10):2864-83
pubmed: 25249672
Nephrol Dial Transplant. 2012 May;27(5):1708-14
pubmed: 22431709
Pharmacol Res Perspect. 2016 May 30;4(4):e00239
pubmed: 28116093
J Diabetes Res. 2013;2013:948257
pubmed: 23691524
Exp Diabetes Res. 2008;2008:305403
pubmed: 18769499
Nat Rev Nephrol. 2012 Feb 21;8(5):293-300
pubmed: 22349487
Nephrol Dial Transplant. 2006 Feb;21(2):324-9
pubmed: 16249198
Kidney Int. 1991 Jun;39(6):1125-34
pubmed: 1895667
Am J Kidney Dis. 2012 Nov;60(5):850-86
pubmed: 23067652
Physiol Res. 2018 Jul 17;67(3):423-432
pubmed: 29527913
J Toxicol Pathol. 2018 Apr;31(2):113-123
pubmed: 29750000
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Nephron. 2019;143(1):3-7
pubmed: 30257247
Kidney Int. 1996 Jun;49(6):1774-7
pubmed: 8743495
World J Gastroenterol. 2015 Aug 14;21(30):9067-78
pubmed: 26290633
Bioinformatics. 2009 Jun 1;25(11):1463-5
pubmed: 19346324
J Atheroscler Thromb. 2012;19(7):608-18
pubmed: 22498767
Physiol Res. 2018 Aug 16;67(4):601-612
pubmed: 29750881
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617
pubmed: 31196815
Exp Anim. 2008 Apr;57(2):111-21
pubmed: 18421173
EBioMedicine. 2018 Oct;36:329-346
pubmed: 30322799
Diabetes Care. 2012 Oct;35(10):2061-8
pubmed: 22773704
Exp Anim. 2014;63(2):121-32
pubmed: 24770637
Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F412-F422
pubmed: 29141939
Kidney Int. 2016 Dec;90(6):1377-1385
pubmed: 27665115
J Pharmacol Toxicol Methods. 2017 Nov - Dec;88(Pt 2):160-166
pubmed: 28970182
Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E563-E576
pubmed: 28811292
Front Endocrinol (Lausanne). 2018 Jul 19;9:412
pubmed: 30072956
Diabetes Care. 2016 Dec;39(12):2278-2287
pubmed: 27703024
Exp Anim. 2005 Jan;54(1):13-20
pubmed: 15725677
Diabetologia. 2011 Aug;54(8):2192-201
pubmed: 21573906
Diabetologia. 2010 Sep;53(9):2056-65
pubmed: 20526760
Int J Exp Diabetes Res. 2000;1(2):89-100
pubmed: 11469401
Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E42-9
pubmed: 14970003
J Am Soc Nephrol. 2017 Apr;28(4):1023-1039
pubmed: 28143897

Auteurs

R Sano (R)

Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan. yukihito.ishii@jt.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH